Table 2.

Virologic response rates for second-line antiretroviral therapy patients using intention-to treat analysis and pre-protocol analysis (48 weeks).

	Using ITT analysis		Using PP analysis
	Range	Combined rate (95%CI)	Range	Combined rate (95%CI)
LPV/r-based regimen	61.89–91.86%	77% (70–84%)	68.15–97.93%	87% (81–93%)
LPV/r+RAL regimen	82.59–91.96%	87% (78–96%)	92.53–97.93%	95% (90–100%)
LPV/r+NRTIs regimen	61.89–90.94%	74% (66–83%)	68.15–94.40%	81% (72–91%)

NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; RAL, raltegravir; LPV/r, ritonavir-boosted lopinavir.